BIB
ProShares Ultra Nasdaq Biotechnology
Set alert
- YTD
- +51.08%
- 1 year
- +72.58%
- Open
- 122.20
- Prev close
- 120.16
- Mkt cap
- 103.65M
- Vol
- 27.15K
- Avg vol
- 9.54K
- EPS
- 3.53
- P/E
- 34.13
- Div yield
- 0.00%
More statistics
- Low
- 120.00
- High
- 125.27
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.00
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 59.52
- 200-d avg
- 59.79
News
3 days ago defenseworld.net
Capital Investment Advisors LLC Acquires New Holdings in ProShares Ultra Nasdaq Biotechnology $BIB
Capital Investment Advisors LLC acquired a new position in shares of ProShares Ultra Nasdaq Biotechnology (NASDAQ: BIB) in the undefined quarter, according to its most recent 13F filing with the…
7 months ago defenseworld.net
ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Stock Price Cross Below 50 Day Moving Average – What’s Next?
ProShares Ultra Nasdaq Biotechnology (NASDAQ: BIB - Get Free Report)'s stock price crossed below its 50-day moving average during trading on Thursday. The stock has a 50-day moving average of $84.02…
10 months ago defenseworld.net
ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Shares Cross Above 50 Day Moving Average – Here’s Why
ProShares Ultra Nasdaq Biotechnology (NASDAQ: BIB - Get Free Report)'s stock price crossed above its 50 day moving average during trading on Friday. The stock has a 50 day moving average of $74.59…
1 year ago seekingalpha.com
BIB: A Tactical 2 X Leveraged Biotech ETF
BIB seeks 2× the daily return of the Nasdaq Biotechnology Index, amplifying both gains and losses through leverage. A higher expense ratio reflects leverage costs and management fees; 24 bps…
2 years ago investorplace.com
Wall Street's Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich
Some of the market's favorite biotech stocks have created immense wealth, as in the recent weight-loss drug stock boom. On May 26, Viking Therapeutics (NASDAQ: VKTX ) was trading around $20.25.
2 years ago investorplace.com
3 Biotech Stocks to Turn $10,000 Into $1 Million: February 2024
With new innovation, high demand for better treatment, pharmaceutical companies strengthening pipelines and a resurgence of mergers and acquisitions, biotech stocks could offer some of the most…
2 years ago seekingalpha.com
Equity CEFs/ETFs: Top Picks For 2024 - Part II
In Part I of my Top Picks For 2024, I explained why we saw such extreme valuation losses in most equity CEFs in 2023 and what that could-mean for 2024. In my opinion, liquidity was the over-riding…
-
3 years ago benzinga.com
Man in Germany Cured of HIV After Undergoing Stem Cell Transplant, According to Report in Nature Medicine
https://www.dailymail.co.uk/health/article-11772327/Man-CURED-HIV-D-sseldorf-patient-virus-free.html?ito=social-twitter_mailonline https://www.nature.com/articles/s41591-023-02213-x
3 years ago investorplace.com
The 7 Best ETFs to Buy to Cover 2023's Biggest Investing Opportunities
These are some of the best ETFs to buy and hold heading into New Year 2023. Rather than being completely tied to the ebb and flow of single-stock ideas, you can gain access to a broad number of…
3 years ago investorplace.com
The 7 Hottest Biotech Stocks to Own in 2023 and Beyond
Some of the hottest biotech stocks are safe and recession-proof. After all, we can't stop people from aging – at least, not yet.
4 years ago seekingalpha.com
Why Now Could Be The Time To Consider Neuroscience Investments
Recognition that aging populations will give rise to new healthcare needs and heightened awareness of mental health issues are bringing renewed focus to neurological health. Recent advances in…
4 years ago etftrends.com
Top Performing Leveraged/Inverse ETFs: 08/07/2022
Top Performing Levered/Inverse ETFs Last Week These were last week's top-performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.
4 years ago etftrends.com
Cap-Weighting Crucial When Indexing Biotech
The biotechnology industry is a bifurcated space. In one corner, you have nascent, small-cap companies that don't yet have steady revenue streams because their new drug or treatment is still in…
-
4 years ago benzinga.com
Psychedelics Company COMPASS Pathways To Join NASDAQ Biotechnology Index
Psilocybin-focused mental health care company COMPASS Pathways plc (NASDAQ: CMPS) revealed Friday that it has been selected for addition to the Nasdaq Biotechnology Index (NASDAQ: NBI), effective as…
4 years ago etftrends.com
How to Invest in Biotech in 2022
It's been a hard year for a lot of the biotech industry, with many hedge funds ending the year with significant losses, but there have been a number of shining stars that are expected to continue to…
5 years ago zacks.com
Take a Look at the Top-Performing Biotech ETFs YTD
The pandemic has triggered a race to introduce vaccines and treatment options, opening up investment opportunities in the biotech sector.
5 years ago zacks.com
Tap the Red Hot Biotech Sector With These 2 Leveraged ETFs
Investors could easily tap the bullish trend by considering a near-term long on the biotech sector.
5 years ago etftrends.com
Pfizer-BioNTech COVID-19 Vaccine Garners Full FDA Approval
The FDA has officially given full approval to Pfizer and BioNTech for their COVID-19 vaccine, potentially making way for more approvals and more vaccine mandates, reports CNBC. It is a move that…
5 years ago etftrends.com
As Covid Cases Mutate, the Biotech Industry Works to Keep Up
As the Delta variant sweeps across the globe, pharmaceutical and biotech companies are working to ensure vaccines continue to cover the population, as well as working on booster doses that can adapt…
5 years ago zacks.com
5 Best Leveraged ETFs of Last Week
We highlight a few leveraged ETF areas that won last week.
6 years ago thelincolnianonline.com
ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Shares Bought by Capital Investment Advisors LLC
Capital Investment Advisors LLC raised its holdings in ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) by 28.4% during the 2nd quarter, according to the company in its most recent Form 13F filing…
6 years ago thelincolnianonline.com
Tower Research Capital LLC TRC Sells 20,453 Shares of ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB)
Tower Research Capital LLC TRC cut its stake in ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) by 95.9% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange…
-
10 years ago benzinga.com
Exclusive: SunTrust Managing Director Discusses Bluebird Bio, A Leader In Gene Therapy
Exclusive: SunTrust Managing Director Discusses Bluebird Bio, A Leader In Gene Therapy
-
10 years ago benzinga.com
Biotechs Are Ripping Following IPAB Ruling
Biotechs Are Ripping Following IPAB Ruling
-
10 years ago benzinga.com
New Study Suggests Drug Prices Have Doubled Since 2011: What's It Mean For The Market?
New Study Suggests Drug Prices Have Doubled Since 2011: What's It Mean For The Market?
-
11 years ago benzinga.com
ProShares Releases 2 New Leveraged Biotech ETFs
ProShares Releases 2 New Leveraged Biotech ETFs
-
12 years ago benzinga.com
Why Investors Should Closely Watch Celgene
Why Investors Should Closely Watch Celgene
-
13 years ago benzinga.com
Seven ETFs On A Roll (BIB, SOCL, TAN)
Seven ETFs On A Roll (BIB, SOCL, TAN)
-
13 years ago benzinga.com
If Stocks Keep Soaring, Get to Know These Leveraged ETFs
If Stocks Keep Soaring, Get to Know These Leveraged ETFs
-
14 years ago benzinga.com
ProShares to Split 2, Reverse Split 9 ETFs
ProShares to Split 2, Reverse Split 9 ETFs
-
14 years ago benzinga.com
Low Volume, High Returns for These ETFs (BIB, FHC, DRW)
Low Volume, High Returns for These ETFs (BIB, FHC, DRW)
-
14 years ago benzinga.com
Nine ETFs on a Roll (DRN, TQQQ, BIB, BGU)
Nine ETFs on a Roll (DRN, TQQQ, BIB, BGU)